Insider Selling: Axon Enterprise, Inc. (NASDAQ:AXON) Director Sells $437,980.00 in Stock

Axon Enterprise, Inc. (NASDAQ:AXON) Director Michael Garnreiter sold 1,000 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total value of $437,980.00. Following the transaction, the director now directly owns 26,259 shares of the company’s stock, valued at approximately $11,500,916.82. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Michael Garnreiter also recently made the following trade(s):

• On Monday, September 16th, Michael Garnreiter sold 1,000 shares of Axon Enterprise stock. The shares were sold at an average price of $380.99, for a total value of $380,990.00.

Axon Enterprise Stock Up 0.8 %

AXON opened at $438.05 on Friday. The company has a market capitalization of $33.10 billion, a PE ratio of 115.58, a price-to-earnings-growth ratio of 11.74 and a beta of 0.94. The business has a 50-day moving average of $388.71 and a 200-day moving average of $331.64. Axon Enterprise, Inc. has a fifty-two week low of $199.29 and a fifty-two week high of $440.89. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same period in the previous year, the company earned $0.80 earnings per share. The company’s revenue was up 34.5% compared to the same quarter last year. Equities research analysts forecast that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Axon Enterprise

Hedge funds have recently bought and sold shares of the business. Blue Trust Inc. boosted its stake in shares of Axon Enterprise by 987.5% during the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 79 shares in the last quarter. Trivant Custom Portfolio Group LLC acquired a new stake in shares of Axon Enterprise in the first quarter worth $31,000. Quent Capital LLC boosted its holdings in shares of Axon Enterprise by 1,875.0% during the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after buying an additional 75 shares during the period. First PREMIER Bank acquired a new position in Axon Enterprise in the 1st quarter valued at $33,000. Finally, Rise Advisors LLC lifted its position in Axon Enterprise by 49.0% during the 1st quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 47 shares during the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on AXON shares. Needham & Company LLC reissued a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a report on Wednesday, August 7th. Barclays raised their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Bank of America began coverage on Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target on the stock. Northland Securities lifted their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Finally, JMP Securities upped their target price on Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus target price of $365.38.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.